Tekla Life Sciences Investors reported earnings results for the full year ended September 30, 2022. For the full year, the company reported revenue was USD 3.02 million. Net loss was USD 104.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.97 USD | +0.15% | +1.33% | -3.64% |
1st Jan change | Capi. | |
---|---|---|
-3.64% | 355M | |
+3.74% | 12.61B | |
+5.50% | 9.01B | |
-3.20% | 5.41B | |
+2.44% | 5.25B | |
+5.63% | 5.19B | |
+14.36% | 4.48B | |
+16.67% | 4.44B | |
+1.53% | 4B | |
+1.56% | 3.75B |
- Stock Market
- Equities
- HQL Stock
- News Abrdn Life Sciences Investors
- Tekla Life Sciences Investors Reports Earnings Results for the Full Year Ended September 30, 2022